1 May 2020 - The May 2020 issue of the Schedule of Pharmaceutical Benefits is out and now in effect.

The May issue of the Schedule includes several new listings:

• Bentalizumab (Fasenra) - new formulation
• Brigatinib (Alunbrig) - new medicine
• Buprenorphine (Sublocade) - new formulation
• Evolocumab (Repatha) - new indication
• Sapropterin dihydrochloride (Kuvan) - new formulation
• Trastuzumab (Trazimera) - new biosimilar medicine
• Upadacitinib monohydrate (Rinvoq) - new medicine

Read Summary of PBS changes